Catalent Pharma Solutions

As the originator of the RP Scherer softgel rotary-die process, Catalent has more than 80 years’ manufacturing experience for the formulation and delivery of pharmaceutical and consumer softgels. Catalent continues to innovate with specialised global manufacturing and technological enhancements such as chewable softgels; enteric coatings to enable delayed-release of the active ingredient with targeted absorption; its breakthrough softgel technologies such as OptiShell™, a plant-derived capsule suitable for complex fill formulations; OptiGel™ Bio for macromolecules; and OptiGel™ Lock designed for abuse deterrence. Further technology advancements in controlled release include Catalent’s OSDrC^® OptiDose™ technology, which enables the design of dividable, multi-layer, single or multi-core tablets with a variety of core shapes, sizes, and flexible placement; providing new alternatives in controlled release designs for drug formulators, developers, and marketers, in a high quality, one-step manufacturing process. Recently, Catalent has made substantial investments in two joint ventures in China to serve its growing customer base in the region. In 2014 the company celebrated its 40th year in Japan with a new, dedicated laboratory to provide proof-of-concept support and feasibility studies for Catalent’s proprietary Zydis^® Orally Dispersible Tablet (ODT) technology, and the announcement that it will also expand manufacturing capacity for its OptiGel Micro™ softgel technology. www.catalent.com E-mail: info@catalent.com

---

---